


LEQVIO® — A SMALL INTERFERING RNA THERAPY THAT SELECTIVELY TARGETS THE LIVER TO REGULATE LDL-C LEVELS IN ADULT PATIENTS WITH HYPERCHOLESTEROLEMIA

LEQVIO®
(inclisiran) injection
284 mg/1.5 mL


HOW IS LDL-C REGULATED?

Cholesterol circulates in plasma within lipoprotein particles.^{1,2} Uptake of these particles by the liver is one of several tightly coordinated processes that maintain cholesterol homeostasis.¹



HOW LEQVIO WORKS

RNA interference (RNAi) is a biological process that regulates gene expression by inhibiting translation of specifically targeted messenger RNA (mRNA) into proteins.⁴ Therapies such as small interfering RNAs (siRNAs) have been developed to mimic the body's process of RNAi.⁵ LEQVIO is an siRNA therapy that was assessed for its efficacy and safety as an LDL-C-lowering therapy.³



STUDIES HAVE SHOWN LEQVIO TO HAVE HIGH SELECTIVITY FOR THE LIVER WITH REDUCED UPTAKE IN OTHER ORGANS⁴

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

IMPORTANT SAFETY INFORMATION

Contraindication: LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema.

IMPORTANT SAFETY INFORMATION (CONT)

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with LEQVIO. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly.

Adverse Reactions: Adverse reactions in clinical trials (≥3% of adult patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

1. Trapani L et al. *World J Hepatol.* 2012;4(6):184-190. 2. Shapiro MD et al. *Circ Res.* 2018;122(10):1420-1438. 3. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 4. Ray KK et al. *N Engl J Med.* 2020;382(16):1507-1519. 5. Khvorova A. *N Engl J Med.* 2017;376(1):4-7.